Evaluation of cardiotoxicity of doxorubicin in rat by a novel metabolic balance model

JIANG Huiyong; YAN Yidan; LIU Haochen; ZHENG Yunsi; WANG Yixuan; HE Hua; LIU Xiaoquan

doi:10.11665/j.issn.1000-5048.20150215

Journal of China Pharmaceutical University > 2015 > 46(2): 224-229. > DOI: 10.11665/j.issn.1000-5048.20150215

JIANG Huiyong, YAN Yidan, LIU Haochen, ZHENG Yunsi, WANG Yixuan, HE Hua, LIU Xiaoquan. Evaluation of cardiotoxicity of doxorubicin in rat by a novel metabolic balance model[J]. Journal of China Pharmaceutical University, 2015, 46(2): 224-229. DOI: 10.11665/j.issn.1000-5048.20150215

Citation:

PDF (2231 KB)

Evaluation of cardiotoxicity of doxorubicin in rat by a novel metabolic balance model

More Information

Graphical Abstract

Abstract

Abstract

The study developed a metabolic balance model to evaluated the cardiotoxicity of doxorubicin. The rats were divided into 3 groups, control group(saline), low dose group(8 mg/kg of cumulative doxorubicin)and high dose group(15 mg/kg of cumulative doxorubicin). Doxorubicin or saline was intraperitoneally injected and blood sample was collected at day 1, 4, 7 and 10. The concentrations of nitric oxide(NO), B-type natriuretic peptide(BNP)and the activity of glutathion peroxidase(GSH-Px), xanthine oxidase(XOD)in rat plasma were determined. A metabolic balance model based on the four biomarkers was developed to evaluate the doxorubicin cardiotoxicity in rat. Doxorubicin leaded to significant changes of multiple biomarkers, resulting in metabolic balance disruption according to the metabolic balance maps and dynamic parameters of metabolic balance disruption. Moreover, the correlation study showed a good relationship between metabolic balance disruption and ejection fraction(EF). The metabolic balance model provide a novel method to integrally evaluate the doxorubicin-induced cardiotoxicity.
- doxorubicin,
- cardiotoxicity,
- metabolic balance model,
- biomarker

FullText(HTML)

References (20)

References

[1]	Iliskovic N,Singal PK.Lipid lowering:an important factor in preventing adriamycin-induced heart failure[J].Am J Pathol,1997,150(2):727.
[2]	From AM,Maleszewski JJ,Rihal CS.Current status of endomyocardial biopsy[C].Mayo Clin Proc,2011,86(11):1095-1102.
[3]	Gharib MI,Burnett AK.Chemotherapy-induced cardiotoxicity:current practice and prospects of prophylaxis[J].Eur J Heart Failure,2002,4(3):235-242.
[4]	Ky B,French B,Levy WC,et al.Multiple biomarkers for risk prediction in chronic heart failure[J].Circ:Heart Failure,2012,5(2):183-190.
[5]	Zethelius B,Berglund L,Sundström J,et al.Use of multiple biomarkers to improve the prediction of death from cardiovascular causes[J].N Engl J Med,2008,358(20):2107-2116.
[6]	Fertin M, Dubois E, Belliard A, et al. Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction[J].Am J Cardiol,2012,110(2):277-283.
[7]	Granados-Principal S,Quiles JL,Ramirez-Tortosa CL,et al.New advances in molecular mechanisms and the prevention of adriamycin toxicity by antioxidant nutrients[J].Food Chem Toxicol,2010,48(6):1425-1438.
[8]	Oemrawsingh RM,Lenderink T,Akkerhuis KM,et al.Multimarker risk model containing troponin-T,interleukin 10,myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome[J].Heart,2011,97(13):1061-1066.
[9]	He H,Wang S,Li X,et al.A novel metabolic balance model for describing the metabolic disruption of and interactions between cardiovascular-related markers during acute myocardial infarction[J].Metabolism,2013,62(10):1357-1366.
[10]	Dai LL,Wan HT,Zhou HF,et al.Protective effect of Guhonginjection on rat cerebral microvascular endothelial cells injured by oxygen glucose deprivation[J].Chin Pharm J(中国药学杂志),2014,49(21):1897-1902.
[11]	Wang J,Jiang Z,Ji J,et al.Evaluation of hepatotoxicity and cholestasis in rats treated with EtOH extract of Fructus Psoraleae[J].J Ethnopharmacol,2012,144(1):73-81.
[12]	Cheng K,Mao S,Zhou Y.Detection of nitric oxide in patients with herpes simplex keratitis by the method of nitric acid reductase[J].Foreign Med Sci(国外医学),2005,26(10):675-677.
[13]	Hasi'c S,Hadovi'c-Duvo A,Jadri'c R,et al.B-type natriuretic peptide and adiponectin releases in rat model of myocardial damage induced by isoproterenol administration[J].Bosn J Basic Med Sci,2013,13(4):225-229.
[14]	Li T,Danelisen I,Belló-Klein A,et al.Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats[J].Cardiovasc Res,2000,46(3):523-530.
[15]	Fadillioglu E,Yılmaz HR,Erdogan H,et al.The activities of tissue xanthine oxidase and adenosine deaminase and the levels of hydroxyproline and nitric oxide in rat hearts subjected to doxorubicin:protective effect of erdosteine[J].Toxicology,2003,191(2):153-158.
[16]	Saavedra WF,Paolocci N,John MES,et al.Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart[J].Circ Res,2002,90(3):297-304.
[17]	Liu B,Li H,Qu H,et al.Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats[J].J Biochem Mol Biol,2006,39(6):759.
[18]	Weinstein DM,Mihm MJ,Bauer JA.Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice[J].J Pharmacol Exp Ther,2000,294(1):396-401.
[19]	Wang TJ,Larson MG,Levy D,et al.Plasma natriuretic peptide levels and the risk of cardiovascular events and death[J].N Engl J Med,2004,350(7):655-663.
[20]	Feola M,Garrone O,Occelli M,et al.Cardiotoxicity after anthracycline chemotherapy in breast carcinoma:effects on left ventricular ejection fraction,troponin I and brain natriuretic peptide[J].Int J Cardiol,2011,148(2):194-198.

Cited By

Get Citation

PDF

XML

Article views (884) PDF downloads (1426)

Turn off MathJax

Article Contents

Abstract

References

Evaluation of cardiotoxicity of doxorubicin in rat by a novel metabolic balance model

Abstract

References

Catalog

Export File

Citation

Format

Content